key: cord-0807739-i93gx61h authors: Rolland, S; Lebeaux, D; Tattevin, P; Launay, O; Luong Nguyen, L B title: Evolution of practices regarding COVID-19 treatment in France during the first wave: results from three cross-sectional surveys (March to June 2020) date: 2021-01-26 journal: J Antimicrob Chemother DOI: 10.1093/jac/dkaa564 sha: d6ea30a16543e4533ae7565dc52796b04ac23b16 doc_id: 807739 cord_uid: i93gx61h nan Sir, At the beginning of the first epidemic wave of COVID-19 in France, physicians had to manage severely ill patients in the absence of any treatment with documented clinical efficacy. Several repurposed drugs have been used for COVID-19 treatment, 1 such as antivirals (remdesivir, lopinavir), immunomodulatory drugs (corticosteroids, tocilizumab, anakinra) or hydroxychloroquine, with poor results for most of them as of today. 2 Throughout the epidemic, their use has been a subject of lively debate in France by the scientific community and in the media. Physicians also rapidly had the possibility to include patients in therapeutic trials. In this context of an initial lack of validated treatment, we aimed to describe physicians' practices during this first epidemic wave of COVID-19 in France. We performed three online surveys among members of the French society of infectious diseases (Société de Pathologie Infectieuse de Langue Française; SPILF) on the 22 March, the 23 April and the 09 June. Surveys were broadcast to the 700 subscribers of the SPILF mailing list. The questionnaires aimed to collect characteristics of the physicians' centres (hospital, service, and region), participation in clinical trials, and drugs used for COVID-19 treatment. The questionnaire mostly used multiple-choice questions. All data were reported as count and percentages in a univariate analysis. Fisher's exact test was used to compare proportions when appropriate. A total of 144 complete questionnaires were collected from 115 physicians: 60 in March, 54 in April and 30 in June. Five physicians answered all three surveys. All regions of metropolitan France were represented. Among the 115 physicians, 54 (47%) were working in a university hospital, and 51 (44%) in a public hospital. Seventy-seven (67%) worked in infectious diseases departments, and 9 (8%) in intensive care units. The characteristics of respondents did not change across time (Table S1 , available as Supplementary data at JAC Online). Participation in trials was reported by 19/60 clinicians (32%) in March, compared with 40/54 clinicians (74%) in April. Participation rate in clinical studies was lower in June (17/30, 57%). The clinical studies were all French, except for one (DisCoVeRy, NCT04315948). Among physicians involved in clinical studies, hospital type differed significantly during the March and April surveys. The proportion working in a non-University hospital increased from 16% (3/19) in March, to 37% (15/40) in April and 53% (9/17) in June (Table S2) . Specific treatment for COVID-19 was reported for 46/60 (77%) questionnaires in March, 35/54 (65%) in April, and 27/30 (90%) in June. From March to June, we observed a shift in drug preferences over time, with a decrease of hydroxychloroquine prescription, whereas the use of immunomodulating drugs as a whole (corticosteroids, tocilizumab and anakinra) increased. There was also a rise in the prescription of remdesivir. Surprisingly, lopinavir/ritonavir prescription remained stable (Figure 1 ). When analysing each survey separately, prescription of specific treatment and choice of drugs did not differ according to clinicians' region, type of hospital, hospitalization unit, or participation in a clinical study. Early on, physicians were hard-pressed to identify any molecules that might be beneficial to patients. They had to consider the prescription of repurposed drugs, such as hydroxychloroquine or lopinavir/ritonavir, as shown by the results of the March and April surveys. As our study went on, results of randomized controlled trials were published. The preliminary results of remdesivir trial published by Beigel et al., 3 showed a benefit of remdesivir in reducing time to recovery compared with placebo. Although limited, these data offered an alternative to hydroxychloroquine, which was banned as a COVID-19 treatment after several studies failed to show benefit for patients, 4,5 and was confirmed later; 6 our June survey captured this prescription shift. By the end of our study, the preliminary report of the RECOVERY trial had been communicated, 7 with a robust outcome showing a reduced mortality for critically ill patients receiving dexamethasone, a finding that has been confirmed over time. 8, 9 Several weeks before this major breakthrough, physicians were already considering using corticosteroids because of pathophysiological data describing an inappropriate immune response in severe COVID-19, resulting in a so-called 'cytokine storm'. 10 In accordance, we observed a continuous rise in the use of various immunomodulatory drugs, and corticosteroids ended up as the favoured drug in June. Despite of its low participation rate caused by the overwhelming workload on physicians, this study still provides new insights in the particular context of an emerging disease, witnessing the pace at which clinicians' practices evolved. Interestingly, practices did not seem to differ according to the characteristics of the centres where clinicians worked, or their access to clinical studies. This longitudinal survey also captured the early impact of clinical studies, though perhaps a more coordinated effort with better access for all physicians might have brought more significant results. Therapeutic options for the 2019 novel coronavirus (2019-nCoV) Repurposed antiviral drugs for COVID-19 -Interim WHO Solidarity trial results Remdesivir for the treatment of COVID-19-final report Avis du haut conseil de la santé publique relatif à l'utilisation de l'hydroxychloroquine dans la COVID-19 Risk of hydroxychloroquine alone and in combination with azithromycin in the treatment of rheumatoid arthritis: a multinational, retrospective study Effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients: a systematic review and meta-analysis Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19 Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis Dexamethasone in hospitalized patients with COVID-19-preliminary report Results were presented during the 21st National Congress of Infectious Disease, in Poitiers, France, 10 September 2020 (oral communication, ID COL7-3). Results were presented during the ESCMID Conference on Coronavirus Disease in September 2020 (e-Poster, abstract ID 00372). This study was conducted as part of our routine work. None to declare. All data associated with this study is available in the main text or the Supplementary data. Tables S1 and S2 are available as Supplementary data at JAC Online.